Why NOX4 Inhibition May Be the Future of Precision Medicine
In today’s complex biomedical landscape, the search for therapies that are both potent and precise...
Promising Breakthrough in Diabetic Retinopathy Treatment: The Potential of GLX7013114
Diabetic retinopathy (DR), a leading cause of blindness among working-age individuals worldwide,...
Effect of NADPH oxidase inhibitors in an experimental retinal model of excitotoxicity
Abstract
NADPH oxidases (NOX) are activated in ischemic conditions leading to increases in reactive...
Bringing Glucox Biotech AB closer to the clinic
Glucox Biotech (GB) has entered into a new exciting phase by adding strong scientific and business...
Eurostars project reaches unique Not-4 inhibitors
The Eurostar supported project ”Neuroprotective therapy for ischemic stroke” a collaboration between...
Glucox receives financing from Vinnova
Glucox Biotech has success in Eurostars grant application and receives financing for compound development...
Agreement with Maastricht University
Glucox Biotech has signed an agreement with Prof. Harald Schmidt of Maastricht University for further...
Agreement with Accelera
Glucox Biotech has signed an agreement with Accelera Srl, Milano, Italy. Accelera will evaluate pharmacokinetics...
SMURF grant to Glucox and Prof. Nils Welsh
Uppsala University and SLU have together with the European Regional Development Fund alloted Glucox...